275 related articles for article (PubMed ID: 38323175)
41. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
42. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
[TBL] [Abstract][Full Text] [Related]
43. Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.
Szymansky A; Kruetzfeldt LM; Heukamp LC; Hertwig F; Theissen J; Deubzer HE; Willing EM; Menon R; Fuchs S; Thole T; Schulte S; Schmelz K; Künkele A; Lang P; Fuchs J; Eggert A; Eckert C; Fischer M; Henssen AG; Rodriguez-Fos E; Schulte JH
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442335
[TBL] [Abstract][Full Text] [Related]
44. Epigenetic Dysregulation in
Epp S; Chuah SM; Halasz M
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069407
[TBL] [Abstract][Full Text] [Related]
45. In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.
Singh A; Meier-Stephenson V; Jayanthan A; Narendran A
Curr Cancer Drug Targets; 2017; 17(6):569-584. PubMed ID: 27875952
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features.
Phan TDA; Nguyen TQ; To NT; Thanh TL; Ngo DQ
J Pathol Transl Med; 2024 Jan; 58(1):29-34. PubMed ID: 38229432
[TBL] [Abstract][Full Text] [Related]
47. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
48. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
49. State of the art in immunotherapy of neuroblastoma.
Jabbari P; Hanaei S; Rezaei N
Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
[TBL] [Abstract][Full Text] [Related]
50. Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract][Full Text] [Related]
51. Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against
Bellamy J; Szemes M; Melegh Z; Dallosso A; Kollareddy M; Catchpoole D; Malik K
Front Oncol; 2020; 10():818. PubMed ID: 32537432
[TBL] [Abstract][Full Text] [Related]
52. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
53. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
54. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
55. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
Karim F; Amin A; Liu M; Vishnuvardhan N; Amin S; Shabbir R; Swed B; Khan U
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627127
[TBL] [Abstract][Full Text] [Related]
56. Using droplet digital PCR to analyze
Lodrini M; Sprüssel A; Astrahantseff K; Tiburtius D; Konschak R; Lode HN; Fischer M; Keilholz U; Eggert A; Deubzer HE
Oncotarget; 2017 Oct; 8(49):85234-85251. PubMed ID: 29156716
[TBL] [Abstract][Full Text] [Related]
57. Clinical characteristics and risk factors of 47 cases with ruptured neuroblastoma in children.
Qin H; Yang S; Cai S; Ren Q; Han W; Yang W; Cheng H; Ma X; Wang H
BMC Cancer; 2020 Mar; 20(1):243. PubMed ID: 32293329
[TBL] [Abstract][Full Text] [Related]
58. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
59. Identification of hub genes and their correlation with infiltration of immune cells in
Chen J; Sun M; Chen C; Jiang B; Fang Y
Front Immunol; 2022; 13():1016683. PubMed ID: 36311753
[TBL] [Abstract][Full Text] [Related]
60. Recent clinical research on the application of liquid biopsy in neuroblastoma.
Liu SY; Wen FQ
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Mar; 24(3):339-344. PubMed ID: 35351268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]